1.

PHP41 LUMP SUM REIMBURSEMENT OF PHARMACEUTICALS IN HOSPITALS IN BELGIUM: ASSESSING THE ADVERSE EFFECTS

1.

PCV162 PUBLIC TENDERING FOR OFF PATENT PHARMACEUTICALS IN BELGIUM—THE SIMVASTATIN CASE

1.

PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT: ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM

1.

PHP31 IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION?—THE ALENDRONATE CASE IN BELGIUM

1.

PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP):ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?